Curcumin-1,2,3-Triazole Conjugation for Targeting the Cancer Apoptosis Machinery

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Oncology

Background:

• Neoplastic diseases represent a significant global mortality burden.
• Existing anticancer therapeutics often exhibit clinical inadequacy and prompt drug resistance.
• Targeting cancer cell apoptosis is a key strategy to overcome therapeutic resistance.

Purpose of the Study:

• To discover novel anticancer agents with potent and safe antitumor profiles.
• To synthesize and evaluate a library of hybrid molecules combining curcumin and 1,2,3-triazole scaffolds.
• To investigate the mechanism of action of promising drug candidates, focusing on apoptosis induction.

Main Methods:

• Utilized click chemistry to synthesize a library of hybrid molecules.
• Screened compounds for cytotoxic activity against T acute lymphoblastic leukemia cells.
• Conducted in-depth biologic studies to elucidate the apoptosis-inducing mechanisms of lead compounds.

Main Results:

• Compound 1, a hybrid molecule featuring a para-fluoro phenyl moiety, demonstrated low-micromolar potency against T acute lymphoblastic leukemia.
• Compound 1 was found to induce cancer cell death by simultaneously activating both receptor-mediated and mitochondrial apoptosis pathways.
• This dual activation mechanism suggests a potential for enhanced cytotoxic response and reduced chemoresistance.

Conclusions:

• Compound 1 exhibits significant potential as an anticancer drug candidate.
• The identified lead compound warrants further progression in preclinical development.
• The study highlights the efficacy of hybrid molecules targeting apoptosis for novel cancer therapy.